Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Board Appointment

7 May 2009 07:00

RNS Number : 8018R
Genus PLC
07 May 2009
Β 

ο»Ώ

For immediate release 7 May 2009

Genus plc

('Genus' orΒ 'the Company')

Board Appointment

Genus, a leading global animal genetics company,Β is pleased to announceΒ the appointment of Mike Buzzacott as a non-executive director.

Mike Buzzacott spent 34 years at BP prior to his retirement in 2004,Β holding a number of international roles including Finance & Control Director Asia Pacific,Β CFO BP Nutrition and Group Vice President Petrochemicals.Β He is currently a non-executive director andΒ AuditΒ Committee chairmanΒ of Rexam Plc (retiring in May 2009) and Croda Plc.Β He is also a non-executive director of Scapa Plc.Β He was Chairman of Biofuels Plc from 2006 until its re-registration in 2007 as a private company.

Mike BuzzacottΒ will chair the Company's Audit Committee and will be a member of the Remuneration Committee.

Commenting onΒ theΒ appointment,Β John Hawkins, Chairman of Genus, said:

"We are delighted to welcome Mike to the Board. He brings with him considerable experience gained in overseas international markets that will greatly benefit Genus during its next stage of strategic development and beyond."

There are no further details to be disclosed in respect of Mike Buzzacott under paragraph 9.6.13R of the Listing Rules of the UK Financial Services Authority.

For further information please contact:

Genus plc Tel: 01256 345970

John Hawkins, Chairman

Richard Wood, Chief Executive

Buchanan Communications Tel: 0207 466 5000

Charles Ryland , Isabel Podda

About Genus

GenusΒ creates advances to animal breeding through biotechnology andΒ sells added value products for livestock farming andΒ food producers. It's non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain.Β 

The Group'sΒ competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered inΒ Basingstoke,Β England, Genus companies operate in 30 countries on six continents, with research laboratories located inΒ Madison,Β USA.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOACKAKDPBKDDPK
Date   Source Headline
26th Feb 20257:00 amRNSNon-Executive Director Retirement
3rd Feb 20253:17 pmRNSBlock Listing Six Monthly Return
3rd Feb 20259:40 amRNSTotal Voting Rights
15th Jan 20257:00 amRNSHalf Year Trading Update – Ahead of expectations
12th Dec 20245:07 pmRNSNotification of Major Holdings
20th Nov 20243:32 pmRNSResults of AGM
20th Nov 20247:00 amRNSAGM Trading Update
1st Nov 202410:42 amRNSTotal Voting Rights
22nd Oct 20247:00 amRNSChief Financial Officer Retirement
14th Oct 20247:00 amRNSAnnual Report and Annual General Meeting
18th Sep 202411:17 amRNSDirector/PDMR Shareholding
16th Sep 20244:29 pmRNSDirector/PDMR Shareholding
12th Sep 20244:51 pmRNSDirector/PDMR Shareholding
12th Sep 20247:00 amRNSDirector/PDMR Shareholding
9th Sep 20247:00 amRNSDirector/PDMR Shareholding
6th Sep 202412:31 pmRNSDirector/PDMR Shareholding
6th Sep 202412:30 pmRNSDirector/PDMR Shareholding
5th Sep 20247:00 amRNSPreliminary Results
1st Aug 20244:26 pmRNSBlock Listing Six Monthly Return
1st Aug 20243:38 pmRNSTotal Voting Rights
17th Jul 20247:00 amRNSTrading Update
3rd Jun 202410:48 amRNSHolding(s) in Company
1st May 20241:59 pmRNSTotal Voting Rights
22nd Feb 20247:00 amRNSInterim Results
15th Feb 20247:00 amRNSTrading Update
1st Feb 20244:24 pmRNSBlock listing Interim Review
1st Feb 20244:21 pmRNSTotal Voting Rights
12th Dec 20237:00 amRNSNon-Executive Director Appointment
22nd Nov 20231:08 pmRNSResult of AGM
22nd Nov 20237:00 amRNSAGM Trading Update
1st Nov 20234:46 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSCapital Markets Event
13th Oct 20237:00 amRNSAnnual Report and Annual General Meeting
5th Oct 202310:19 amRNSPos. determination-PRRS resistant pigs-Colombia
2nd Oct 202311:12 amRNSTotal Voting Rights
15th Sep 20231:07 pmRNSDirector/PDMR Shareholding
15th Sep 202310:04 amRNSDirector/PDMR Shareholding
7th Sep 20237:00 amRNSPreliminary Results
25th Aug 20238:35 amRNSNotification of Major Holdings
23rd Aug 20239:25 amRNSDirectorate Change
1st Aug 202311:41 amRNSBlock listing Interim Review
1st Aug 202311:36 amRNSTotal Voting Rights
3rd Jul 202311:02 amRNSTotal Voting Rights
16th Jun 20235:33 pmRNSNational Milk Records plc - Form 8.3
16th Jun 20235:10 pmRNSForm 8.3 (OPD) - National Milk Records plc
8th Jun 20233:51 pmRNSDirector/PDMR Shareholding
7th Jun 20235:11 pmRNSNotification of Major Holdings
7th Jun 20235:08 pmRNSNotification of Major Holdings
5th Jun 20239:12 amRNSAdditional Listing
24th May 20234:54 pmRNSNotification of Major Holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.